• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23378 Records] Selected Records [0 Hits] [Clear]
Year Source Title
1999     Finnish Office for Health Care Technology Assessment (Finohta) [From science to practice - systematic reviews in health care]
2003     The Netherlands Organisation for Health Research and Development (ZonMw) [From efficacy to effectiveness in cancer research]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fremanezumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fremanezumab (migraine) - Addendum to Commission A19-44]
2005     Andalusian Health Technology Assessment Area (AETSA) [Framework for the assessment of genetic testing in the Andalusian public health system]
2021     Canary Health Service [Framework for relations between the Spanish Network of HTA agencies of the NHS with industry]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fracture sonography in children with suspected fracture of a long tubular bone of the upper extremities]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional flow-reserve by intracoronary pressure guidewire in patients with acute coronary syndrome]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional flow reserve in coronary artery]
2015     Haute Autorite de sante (HAS) [Fractional flow reserve (FFR) measurement during coronary angiography]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021     Canary Health Service [Foot reflexology]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Food in diabetes]
2007     Health Council of the Netherlands Gezondheidsraad (GR) [Food allergy]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [FONAKIDs® multimodal approach in congenital or acquired apraxia of speech]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-up visits from nurses after discharge from multidisciplinary pain centre - a health technology assessment]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-up in gynaecological cancer patients - a health technology assessment]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-Up for gynecological cancer]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Foetal growth retardation at term: induction of labour or not? A comparison of maternal and neonatal outcome, maternal quality of life and costs (DIGITAT). The Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT)]
2023     HTA South [Focused ultrasound treatment for tremor]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [FOAM-study. Cost minimization study comparing surgery versus duplex guided foam sclerotherapy of varicose veins: a randomized controlled study]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-15]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fluorodopa PET scanning in Parkinson’s disease]
2010     Finnish Office for Health Care Technology Assessment (Finohta) [Fluorescence cystoscopy in diagnosis and management of superficial bladder cancer]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Flashglucose monitoring system (Freestyle Libre, Abbott), report updated April 8 2020]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fixed combinations of corticosteroids and long-acting beta-2-receptor agonists for inhaled use in patients with asthma]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fixed combinations of corticosteroids and long-acting beta-2-receptor agonists for inhaled use in patients with asthma - supplementary commission]
2015     Norwegian Knowledge Centre for the Health Services (NOKC) [First aid training may improve first aid skills]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Fingolimod for relapsing/remitting multiple sclerosis (RRMS)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Addendum to Commission A15-48]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 2 and 3) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) – Addendum to Commission A23-14]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) - Benefit assessment according to §35a Social Code Book V]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Financing procedures in primary care adequate for resources and efficiency, by means of adjusted clinical groups (ACG)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [FilmArray® in Acute Respiratory Infections and Sepsis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2014     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Field evaluation of the initial treatment of STEMI in Quebec's hospitals - phase 2]
2020     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Field evaluation of the implementation of video teleconsultations during the COVID-19 pandemic at the Quebec Heart and Lung Institute]
2013     Andalusian Health Technology Assessment Area (AETSA) [Fidaxomicin for the treatment of clostridium difficile infection]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fidaxomicin (clostridioides difficile infection) - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fidaxomicin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fidanacogene elaparvovec (haemophilia B); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Fibromyalgia and chronic fatigue syndrome: recommendations on diagnosis and treatment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2010     Committee for New Health Technology Assessment (CNHTA) [Fiberoptic endoscopic evaluation of swallowing]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fezolinetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Fetoscopic laser photocoagulation in twin-twin transfusion syndrome]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Fetal neurosonography in suspected central nervous system abnormalities]
2012     Finnish Office for Health Care Technology Assessment (Finohta) [Fetal intrapartum surveillance - Does STAN improve safety? A meta-analysis]
2016     The Swedish Council on Health Technology Assessment (SBU) [Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Spectrum Disorders (FASD) – conditions and interventions]
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Fertility preservation in girls and young women in whom potentially gonadotoxic treatment is planned or has been performed]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Ferrara corneal ring for treating keratoconus]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fenfluramine (Lennox-Gastaut syndrome, add-on therapy, = 2 years) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fenfluramine (Dravet syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2010     The Regional Health Technology Assessment Centre (HTA-centrum) [Fenestrated aortic repair of aortic aneurysm]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Femoral neck fracture: evaluation of the hospital care process]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fedratinib (myelofibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Federal structures of the prevention of alcohol misuse among children and youths]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Federal structures and associated behavioural interventions in prevention of cigarette smoking]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fecal microbiota transplantation for recurrent Clostridioides difficile infection]
2024     Gesundheit Osterreich GmbH (GOeG) [Fecal immunochemical tests in comparison: umbrella review]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Fecal calprotectin: diagnostic marker and treatment assessment in bowel inflammatory disease]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Feasibility and appropriateness of implementing satellite radiotherapy centres equipped with a single linear accelerator]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Fear of childbirth, depression and anxiety during pregnancy]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [FDG-PET for avoidance of futile direct laryngoscopies under general anaesthesia with taking of biopsies in patients with suspicion on recurrent laryngeal carcinoma after radiotherapy]
2010     Committee for New Health Technology Assessment (CNHTA) [FBN1 exon deletion test[MLPA]]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Fast-track colonic surgery: a health technology assessment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (visual impairment due to diabetic macular oedema) - Benefit assessment acc. to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (neovascular age-related macular degeneration) - Benefit assessment according to § 35a Social Code Book V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fampridine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2006     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Familial hypercholesterolemia: evaluation of genetic screening by DNA microarrays]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Falls prevention for the elderly]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Falls prevention for the elderly]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Falls in patients living in health care facilities (short- and long-term care)]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Falling in line with the guidelines. Development and pilot testing of an implementation strategy to increase physiotherapists' adherence to evidence-based guidelines for patients with low back pain; a planned, systematic, and theory-based approach]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Fall-safe assist. Portable device for falls prevention]
2011     Health Council of the Netherlands Gezondheidsraad (GR) [Fair compensation. Consideration of a proposal to give live kidney donors priority for transplants]
2017     Andalusian Health Technology Assessment Area (AETSA) [Faecal microbiota transplant for recurrent clostridium difficile infection. Up-date]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fact sheet: Screening for gestational diabetes - rapid report]
2008     Committee for New Health Technology Assessment (CNHTA) [Facioscapulohumeral muscular dystrophy, D4Z4 analysis, PFGE/Southern Blot]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Facility planning and infection prevention: sanitary facilities in specialized care rooms and cubicles]
2009     Committee for New Health Technology Assessment (CNHTA) [F7 gene, mutation[sequencing]]
2009     Committee for New Health Technology Assessment (CNHTA) [F12 gene, mutation[sequencing]]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ezetimibe for the prevention of cardiovascular events - Rapid report]